Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer

published 8 months ago by Dr Neil Love

Featuring a discussion on recent clinical trial data on the use of immune checkpoint inhibitors and other novel therapies in the management of urothelial bladder cancer with Dr Ashish Kamat, including on the following topics: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Treatment of Urothelial Bladder Cancer (UBC) — Ashish M Kamat, MD, MBBS (0:00) Case: A woman in her early 60s with high-grade, BCG-unresponsive non-muscle-invasive bladder cancer who elected not to undergo cystectomy receives pembrolizumab (25:23) Case: A man in his late 60s with a history of low-grade UBC experiences a recurrence 6 years later with T1 high-grade carcinoma in situ (28:07) CME information and select publications

more episodes from Research To Practice | Oncology Videos